On July 20, 2022, BigHat Biosciences, a biotechnology company developing safer, more effective antibody therapies for patients using machine learning and synthetic biology, announced the completion of a Series B financing of $75 million led by Section 32, with participation from new investors Amgen Ventures, Bristol Myers Squibb, Quadrille Capital, Gaingels, and GRIDS Capital. Prior investors Andreessen Horowitz, 8VC, and AME Cloud Ventures also contributed to this round. The company has raised over $100 million to date. Wilson Sonsini Goodrich & Rosati provides support in IP and licensing matters to BigHat Biosciences.
BigHat Biosciences is using MillinerTM, an integrated AI/ML- wet lab platform, to design safer, more effective antibody therapies to treat some of the world’s most intractable conditions, from chronic illnesses to life-threatening diseases. The additional investment will be used to scale the capacity of Millner, advance the internal pipeline of therapeutics to patients, and accelerate strategic partnerships.
The Wilson Sonsini team that advises BigHat Biosciences includes:
Patents and Innovations
Vern Norviel
Julia Minitti
Hee Min Noh
Pete Amos
Technology Transactions
Ian Edvalson
Nellie Brutocao
For more information, please see BigHat Biosciences' news release.